Corporate Overview November 2022 2 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to the potential approval and launch of SER-109; the anticipated indication for SER-109; the anticipated supply of SER-109; the potential for microbiome therapeutics to protect against infection; the timing of clinical results; our development opportunities and plans; the ultima ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2022 Earnings Conference Call November 2, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President & Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - Chief Financial Officer Teresa Young - Chief Commercial & Strategy Officer Conference Call Participants Peyton Bohnsack - Cowen Ted Tenthoff - Piper Sandler Mark Breidenbach - Oppenheimer John Newman - Ca ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Carlo Tanzi - Head of IR Eric Shaff - President & CEO Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - CFO Terri Young - Chief Commercial and Strategy Officer David Ege - Chief Technology Officer Conference Call Participants Mark Breidenbach - Oppenheimer Peyton Bohnsack - Cowen John Newman - Canaccord Ted Tenthoff - Piper Sandler Chris Howert ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET Company Participants | --- | |-----------------------------------------------------| | | | Carlo Tanzi - Head of Investor Relations | | Eric Shaff - President and Chief Executive Officer | | Lisa von Moltke - Chief Medical Officer | | Matthew Henn - Chief Scientific Officer | | David Arkowitz - Chief Financial Officer | | Terri Young - Chief Commercial and Strategy Officer | | David Ege - Chief Technology Officer ...

Corporate Overview March 2022 2 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential approval of SER-109 and its status as a first-in-class therapeutic, the timing of a BLA filing, the market for SER-109, and our capacity for commercial supply of SER-109; the anticipated indication and potential impact of infection protection microbiome therapeuti ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2021 Earnings Conference Call March 1, 2022 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - President and Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn - Chief Scientific Officer David Arkowitz - Chief Financial Officer Terri Young - Chief Commercial and Strategy Officer Conference Call Participants Edward Tenthoff - Piper Sandler Peyton Bohnsack - Cowen Inc. John Newman - Canaccord Genuity Group Inc. Gobi ...

Call Start: 8:30 January 1, 0000 9:13 AM ET Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2021 Earnings Conference Call November 10, 2021, 8:30 AM ET Company Participants Carlo Tanzi ??? Investor Relations Eric Shaff ??? President and Chief Executive Officer Lisa von Moltke ??? Chief Medical Officer David Arkowitz ??? Chief Financial Officer Matthew Henn ??? Chief Scientific Officer Terri Young ??? Chief Commercial and Strategy Officer David Arkowitz ??? Chief Technology Officer Conference Call Participants Jos ...

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q2 2021 Earnings Conference Call August 3, 2021 8:30 AM ET Company Participants Carlo Tanzi - IR Eric Shaff - President and CEO David Arkowitz - CFO Matthew Henn - Chief Scientific Officer Lisa von Moltke - Chief Medical Officer Terri Young - Chief Commercial and Strategy Officer Conference Call Participants Mark Breidenbach - Oppenheimer John Newman - Canaccord Genuity Chris Howerton - Jefferies Ted Tenthoff - Piper Sandler Peyton Bohnsack - Cowen Chris Shibutani - Go ...

Eric Shaff Chief Executive Officer Jefferies Virtual Healthcare Conference June 1, 2021 2 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potential impact of any of our microbiome therapeutics, the ability of our clinical trials to support approval, the timing and results of clinical studies, the timing and ultimate r ...

Corporate Overview May 2021 2 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potential impact of any of our microbiome therapeutics, the ability of our clinical trials to support approval, the timing and results of clinical studies, the timing and ultimate results of the SER- 109 safety data, the size of the market f ...